Fulgent Genetics Inc. (NASDAQ: FLGT) will present interim results from its Phase 2 study of cancer drug FID-007 at the American Society of Clinical Oncology annual meeting on June 1, 2026, according to a company statement.

The presentation will focus on FID-007 combined with cetuximab for treating recurrent or metastatic head and neck squamous cell carcinoma in patients who experienced disease progression after PD-1-based immune checkpoint inhibitor treatment.

The open-label, randomized Phase 2 study (NCT06332092) evaluated two different dosing regimens of FID-007. As of December 20, 2025, data from 42 patients showed an objective response rate of 60%, with 58% in one treatment arm and 61% in another. The median progression-free survival reached 7.2 months overall, with 6.7 months in one arm and 7.2 months in the other.

The median duration of response was 7.4 months, with 56% of responders continuing to respond at the data cutoff date. Overall survival data remain incomplete.

Safety data showed mostly grade 1-2 treatment-related adverse events. Grade 3-4 events occurring in two or more patients included neutropenia, anemia, leukopenia, acneiform dermatitis, and rashes. The study recorded one grade 5 treatment-related adverse event involving pneumonia.

The abstract presentation is scheduled for 4:30 p.m. to 6:00 p.m. Central Daylight Time in Hall D1 of McCormick Place, Chicago, as part of the Head and Neck Cancer Track Rapid Oral Abstract Session.

Fulgent operates laboratory services and therapeutic development businesses, with the latter focused on cancer drug candidates using nanoencapsulation and targeted therapy platforms.